EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia

Mikiko Okazaki-Hada iD, Mototsugu Nagao iD, Akira Asai, Miki Okada-Iwabu, Naomi Hizuka, Lena Eliasson iD, Hitoshi Sugihara, Izumi Fukuda iD, Masato Iwabu iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae879 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Mikiko Okazaki-Hada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan. Hauptthemen laut MEDLINE: Insulin-Like Growth Factor II, Hypoglycemia, MicroRNAs, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Foundation for Growth Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

In most cases of non–islet cell tumor hypoglycemia (NICTH), high molecular weight forms of insulin-like growth factor II, commonly referred to as big IGF-II, cause hypoglycemia. MicroRNA-483 (miR-483), encoded within an intron of IGF2, has been suggested to be coexpressed with IGF-II.

Objective

The aim of this study is to demonstrate the utility and reliability of circulating miR-483 as a biomarker for diagnosis and therapeutic outcome of NICTH.

Methods

Sera from 145 cases of suspected NICTH, and postoperative sera from 25 surgical cases of confirmed NICTH were subjected to Western blot analysis and enzyme-linked immunosorbent assay for IGF-II and quantitative polymerase chain reaction analysis for miR-483-5p and -3p. Tissue miR-483 expression levels were compared between resected solitary fibrous tumors (SFTs) and their surrounding margins from 11 surgical cases.

Results

NICTH was confirmed in 100 out of 145 cases based on the detection of big IGF-II in their sera. Receiver operating characteristic curve analysis revealed that serum miR-483-5p had a better diagnostic ability for NICTH than serum IGF-II or the classical diagnostic marker the IGF-II to IGF-I ratio. Notably, serum miR-483-5p levels decreased significantly with the disappearance of big IGF-II after surgical tumor resection. Tissue miRNA-483-5p and -3p expression levels were significantly higher in resected SFT tissues than in their surgical margins.

Conclusion

Circulating miR-483-5p, derived from IGF-II-producing tumors, appears to be a more reliable biomarker for diagnosis and therapeutic outcome of NICTH than IGF-II or the IGF-II to IGF-I ratio. These findings highlight the clinical utility of miR-483-5p in the management of NICTH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin-Like Growth Factor IIHypoglycemiaMicroRNAsBiomarkers, TumorCirculating MicroRNAHumansFemaleMaleMiddle AgedAgedAdultBiomarkers

Stichwörter der Autor:innen

IGF-IIMicroRNANon-islet cell tumor hypoglycemia

Substanzen

Insulin-Like Growth Factor IIMIRN483 microRNA, humanMicroRNAsIGF2 protein, humanBiomarkers, TumorCirculating MicroRNABiomarkers

Autor:innen und Institutionen

  • Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan.
  • Islet Cell Exocytosis, Department of Clinical Sciences Malmö, Lund University, 214 28 Malmö, Sweden.
  • Department of Biochemistry, Kagawa University Faculty of Medicine, Kagawa 761-0793, Japan.
  • Tokyo Women's Medical University, Shinjuku-ku, Tokyo 162-8666, Japan.

ORCID-Profile: Mikiko Okazaki-Hada, Mototsugu Nagao, Lena Eliasson, Izumi Fukuda, Masato Iwabu

Förderung

  • JSPS KAKENHI
  • Foundation for Growth Science

Zitieren

APA

Okazaki-Hada, M., Nagao, M., Asai, A., Okada-Iwabu, M., Hizuka, N., Eliasson, L., Sugihara, H., Fukuda, I., & Iwabu, M. (2025). Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae879

Vancouver

Okazaki-Hada M, Nagao M, Asai A, Okada-Iwabu M, Hizuka N, Eliasson L, et al. Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae879

BibTeX
@article{OkazakiHada2025,
  author = {Okazaki-Hada, Mikiko and Nagao, Mototsugu and Asai, Akira and Okada-Iwabu, Miki and Hizuka, Naomi and Eliasson, Lena and Sugihara, Hitoshi and Fukuda, Izumi and Iwabu, Masato},
  title = {Potential Utility of Circulating MicroRNA-483 as a Biomarker for IGF-II–Associated Non–Islet Cell Tumor Hypoglycemia},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae879}
}
Kostenlos starten →